Transcript Executive Leadership Meeting Business Development Update

Invitro Testing of Anti-Biofilm Burn
and Wound Care Formulations
Scott Tufts, Vice President
Cardinal Health, Infection Prevention
Acknowledgements:
•Dr. Paul S. Attar, President, Bridge PTS
(Preclincal Testing Services), San Antonio, TX
•Mr. Kan Lam, Vice President, Bridge PTS
(Preclincal Testing Services), San Antonio, TX
•Miss Yanira Hernandez, Scientist, Enturia, Inc.
The Way We Used to Think About
Bacteria
The Real World of Chemotactic
Communication
Bean Sprouts with E. coli O157:H7
E coli on Spinach
Biofilms on Fresh Vegetables

According to statistics from the Centers for
Disease Control and Prevention (CDC) in
Atlanta, only 0.6 percent of disease
outbreaks from food in the 1970s could be
traced to fresh produce. However, since
1998, the percentage has jumped up to
14%.
Now We Know About the EPS
The Biofilm Process
Biofilms and Human Disease

It is estimated that over 80% of all microbial
infections of the human body are associated with
biofilm structure for example:








Acne
Tuberculosis
Periodontal Disease
Pneumonia
Osteomyelitis
Ear, Nose, and Throat Infections
All Catheter and Percutaneous Device Infections
All Wound and Burn Infections
Problems Presented by Biofilms

It is difficult to deliver antimicrobial agents through
the exopolysaccharide matrix at effective
concentrations. Concentrations required to penetrate
the biofilm are thousands of times greater than
necessary to treat planktonic bacteria. Often higher
than the toxicity threshold of the antibiotic!

The cells at the base of the biofilm are operating at a
very low metabolic rate, they are hibernating, waiting
for a nutrient source to revive them. This low
metabolic rate of the sessile organisms, drastically
reduces the effectiveness of antibiotics and promotes
antibiotic resistance.
Infected Burns and Wounds
Testing Objectives
Testing Objective / Challenge:
To utilize laboratory methods to screen and
evaluate trial formulations for their potential to
eliminate biofilms found in burns and wounds.
Methods Development:
Laboratory methods must be validated to
produce reliable and reproducible results.
Methods must be cost effective at screening
large numbers of samples (dose ranging)
Basic MRD Experimental Setup
Biofilm Structure

The Biofilms tested were “complex
biofilms” containing approximately equal
portions of:



Pseudomonas aeruginosa (ATCC 27317)
Staphylococcus aureus (ATCC 25923)
Escherichria coli (ATCC # 47022)
Actual Biofilm Device Set Up
Note- In actual operation media flask would be
immersed in a heated water bath
Actual Biofilm Device Set Up
Note- MRD sits in a heated Aluminum block
Secondary Device for Antimicrobial
Gel Testing
Experimental Logic Flow

Determine the effective concentrations for the
disruption agent in the vehicle

Determine the effectiveness of the antimicrobial
at various levels in the vehicle

Verify that in combination with the disruption
agent, the antimicrobial agent exhibits
effectiveness at lower concentrations
END